09.17.19
Parexel has formed alliances with three healthcare institutions: PKUCare Luzhong Hospital, West China Medical Center, and Shanghai Xuhui Central Hospital, to provide enhanced support for customers conducting Phase I studies in China.
“Parexel has seen a consistent increase in the number of Phase I studies both in healthy subjects and patients being conducted in China in recent years,” said Gadi Saarony, Executive Vice President and Chief Clinical Research Services Officer. “While there is great opportunity in the region, many companies struggle with having the local infrastructure required to initiate Early Phase studies quickly and efficiently, which is critical to success in the long-term. Through these local partnerships, Parexel is able to provide on-the-ground support for rapid start-up and study execution, complementing our proven Early Phase Clinical Pharmacology expertise, along with project and data management and regulatory consulting capabilities with the aim of providing customers with proven strategies for success in China.”
The Early Phase alliances in China were formalized following the successful completion of several Phase I studies, and the establishment of collaboration agreements and operational systems between Parexel and the local institutions. The alliances expand Parexel’s capabilities in the region to provide global and local biopharmaceutical companies with: access to over 250 clinical research beds, rapid study start-up leveraging local resources, a dedicated local Parexel Clinical Pharmacologist and Project Managers to streamline communications and processes, access to to support for local ethics applications and regulatory requirements, and experienced Chinese Quantitative Clinical Development/Data Management/Biostatistics/Programming/Medical writing team.
Parexel has eight offices and more than 1,700 employees across all functions in Greater China as well as more than 8,000 employees in the Asia/Pacific region.
“Parexel has seen a consistent increase in the number of Phase I studies both in healthy subjects and patients being conducted in China in recent years,” said Gadi Saarony, Executive Vice President and Chief Clinical Research Services Officer. “While there is great opportunity in the region, many companies struggle with having the local infrastructure required to initiate Early Phase studies quickly and efficiently, which is critical to success in the long-term. Through these local partnerships, Parexel is able to provide on-the-ground support for rapid start-up and study execution, complementing our proven Early Phase Clinical Pharmacology expertise, along with project and data management and regulatory consulting capabilities with the aim of providing customers with proven strategies for success in China.”
The Early Phase alliances in China were formalized following the successful completion of several Phase I studies, and the establishment of collaboration agreements and operational systems between Parexel and the local institutions. The alliances expand Parexel’s capabilities in the region to provide global and local biopharmaceutical companies with: access to over 250 clinical research beds, rapid study start-up leveraging local resources, a dedicated local Parexel Clinical Pharmacologist and Project Managers to streamline communications and processes, access to to support for local ethics applications and regulatory requirements, and experienced Chinese Quantitative Clinical Development/Data Management/Biostatistics/Programming/Medical writing team.
Parexel has eight offices and more than 1,700 employees across all functions in Greater China as well as more than 8,000 employees in the Asia/Pacific region.
